Coherus BioSciences, Inc. CHRS Income Statement

Coherus biosciences, inc. (CHRS)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Sep'13
Revenue:
Total revenue
435,171	356,071	232,217	120,533	37,100	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration and license revenue
-	-	-	-	-	-	-	-	-	-	0	164,605	177,278	-	199,460	43,792	36,590	30,041	25,604	34,489	32,588	30,374	25,119	0	0	0
Total revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-
Operating expenses:
Cost of goods sold
21,708	17,078	9,273	2,826	2,225	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Research and development
108,506	94,188	85,902	95,937	103,573	110,239	115,065	126,088	134,069	162,389	189,911	211,858	242,902	254,440	246,863	250,508	241,908	213,062	188,496	138,774	100,755	78,224	56,291	0	0	0
Selling, general and administrative
139,704	137,037	134,807	128,348	110,283	94,177	75,315	63,935	69,077	71,303	71,619	71,275	59,002	51,597	47,275	43,796	41,353	36,046	31,260	25,073	20,234	17,564	13,733	0	0	0
Total operating expenses
269,918	248,303	229,982	227,111	216,081	204,416	190,380	190,023	203,146	233,692	261,530	283,133	301,904	306,037	294,138	294,304	283,261	249,108	219,756	163,847	120,989	95,788	70,024	0	0	0
Income (loss) from operations
165,235	107,768	2,233	-106,580	-178,983	-204,416	-190,380	-190,023	-201,751	-232,136	-259,130	-117,898	-123,996	-115,931	-94,678	-250,512	-246,671	-219,067	-193,420	-128,626	-87,669	-64,682	-44,905	0	0	0
Interest expense (includes related party of $620 and $610 for the three months ended March 31, 2020 and 2019, respectively)
17,816	17,601	15,552	13,508	11,492	9,684	9,650	9,617	9,584	9,552	9,521	9,549	9,519	7,980	5,644	0	0	-	0	-	-	3,900	5,892	0	0	0
Other income, net
1,865	2,608	2,227	2,280	5,364	4,691	4,148	3,591	3,569	3,402	3,490	5,123	-3,557	-3,877	-4,135	-6,017	-1,096	-4,838	-6,928	-8,183	-14,018	-18,595	-28,830	0	0	0
Net income (loss) before income taxes
149,284	92,775	-7,322	-98,897	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income tax provision
3,800	2,900	898	51	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)
145,437	89,833	-11,990	-117,859	-185,111	-209,409	-195,882	-196,049	-207,766	-238,286	-265,161	-122,324	-137,072	-127,788	-104,424	-259,753	-248,637	-223,938	-200,381	-136,810	-102,846	-87,177	-79,627	0	0	0
Net loss attributable to non-controlling interest
-	-	0	-18	-	-70	-72	-58	-77	-116	-137	-228	-345	-451	-617	-673	-714	-678	-531	-493	0	-	0	0	-	-
Net income (loss)
145,409	89,833	-11,990	-117,841	-185,046	-209,339	-195,810	-195,991	-207,689	-238,170	-265,024	-122,096	-136,727	-127,337	-103,807	-259,080	-247,923	-223,260	-200,003	-136,541	-102,688	-87,133	-79,472	0	0	0
Net loss per share attributable to Coherus, basic and diluted
-	-	-	-	-	-	-	-	-0.74	-	-1.09	-1.08	-1.54	-	-	-1.72	-1.67	-	-	-1.56	-1.22	3.14	-1.79	-5.96	-6.03	-6.23
Weighted-average number of shares used in computing net loss per share attributable to Coherus, basic and diluted
-	-	-	-	-	-	-	-	60,122	-	54,070	51,291	48,711	-	-	40,698	39,095	-	-	37,672	33,377	19,972	4,409	4,186	4,177	3,444
Net income (loss) per share:
Basic
0.50	0.57	0.67	0.34	-0.29	-	-0.87	-0.68	-	-	-	-	-	-	1.93	-	-	-	-1.86	-	-	-	-	-	-	-
Diluted
0.48	0.57	0.63	0.32	-0.29	-	-0.87	-0.68	-	-	-	-	-	-	1.67	-	-	-	-1.86	-	-	-	-	-	-	-
Weighted-average number of shares used in computing net income (loss) per share:
Basic
70,662	70,222	69,877	69,479	69,140	-	67,848	63,960	-	-	-	-	-	-	43,469	-	-	-	38,426	-	-	-	-	-	-	-
Diluted
74,416	72,108	78,530	72,963	69,140	-	67,848	63,960	-	-	-	-	-	-	51,581	-	-	-	38,426	-	-	-	-	-	-	-